TK-216

N/A

Report date: 2024/04/16 17:47:49
NME

Base Information

Drug NameTK-216
Drug Alias NameTK-216ONCT- 216I-036I036
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEWS-Fli1 protein inhibitorsProto-oncogene proteins c-ets inhibitors
TargetsEWS-Fli1 proteinProto-oncogene proteins c-ets
Therapy Area/IndicationsSarcoma, EwingLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesOncternal Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLyophilization Services Of New England IncShanghai Pharmaceutical (USA) IncShanghai Pharmaceuticals Holding Co Ltd
Inactive CompaniesOncternal Therapeutics IncThe University Of Texas MD Anderson Cancer Center
Active IndicationsSarcoma, Ewing
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A